Feb 22, 2024 / 12:00PM GMT
Susan Ringdal - Hikma Pharmaceuticals PLC - EVP, Strategic Planning And Global Affairs, Member of the Executive Committee
Good morning, and good afternoon, everyone. Thank you very much for joining Hikma's 2023 full-year Results Q&A. I'm very happy to have Riad Mishlawi, Hikma's CEO, on the call today, along with our CFO, Khalid Nabilsi; Bill Larkins, the Head of our Injectables business; Mazen Darwazah, the Head of our Branded business; and Brian Hoffmann, who heads up our Generics business. Mazen Darwazah is on the phone, and the rest of us should be on your screen.
We are going to have Riad give some introductory comments, and then we will open up for Q&A. So I'll hand over now to Riad. Thanks, Riad.
Riad Mishlawi - Hikma Pharmaceuticals PLC - Member of the Executive Committee, President, Injectables
Thank you, Susan, and thank you, everyone, for joining us to discuss the 2023 results. Before we get to the Q&A, I would like to give you a few high-level thoughts on our 2023 performance and go a little bit on the 2024 outlook.
Let
Full Year 2023 Hikma Pharmaceuticals PLC Earnings Call Transcript
Feb 28, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers